Pulmonx (LUNG) Net Cash Flow Growth (1y) (2020 - 2025)
Pulmonx (LUNG) Net Cash Flow Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 157.80 Bn | 151.14 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 115.54 Bn | 112.66 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 103.44 Bn | 95.27 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 72.38 Bn | 71.17 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 49.76 Bn | 46.09 Bn | 1.29 Bn | -564.44% |
| 6 | Dexcom | 29.53 Bn | 28.42 Bn | 750.30 Mn | -31.84% |
| 7 | GE HealthCare Technologies | 29.51 Bn | 27.44 Bn | 1.98 Bn | -394.13% |
| 8 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 9 | Steris | 20.69 Bn | 20.27 Bn | 697.10 Mn | 57.36% |
| 10 | Pulmonx | 62.51 Mn | -7.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 6,900.00% |
| Jun 30, 2025 | 122.58% |
| Mar 31, 2025 | 128.11% |
| Dec 31, 2024 | 166.37% |
| Sep 30, 2024 | 100.14% |
| Jun 30, 2024 | 22.72% |
| Mar 31, 2024 | -254.57% |
| Dec 31, 2023 | -6.42% |
| Sep 30, 2023 | 26.65% |
| Jun 30, 2023 | -17.24% |
| Mar 31, 2023 | 144.97% |
| Dec 31, 2022 | 73.62% |
| Sep 30, 2022 | 9.12% |
| Jun 30, 2022 | 30.59% |
| Mar 31, 2022 | 12.98% |
| Dec 31, 2021 | -120.68% |
| Sep 30, 2021 | -198.61% |
| Jun 30, 2021 | -139.03% |
| Mar 31, 2021 | -1,550.26% |
| Dec 31, 2020 | 22,300.23% |